Interim report
Page 1
4th November, 2026 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 Scrip Code: 533573 To, The Manager, Listing Department, National Stock Exchange of India Ltd. 'Exchange Plaza', Sandra Kurla Complex, Sandra (E), Mumbai - 400 051 NSE Symbol: APLL TD Dear Sir/ Madam, Sub: Outcome of Board Meeting held on 4th November, 2026 With reference to the captioned matter, the stock exchanges are hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today inter-alia has approved the Consolidated and Standalone Unaudited Financial Results along with the Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended 301h September, 2026. The time of commencement of Board Meeting was 11 :30 a.m. and the time of conclusion was 2:10 p.m. We request you to kindly take the same on record. Thanking you, Yours faithfully, F lembic Pharmaceuticals Limited - 1rag K. Shukla Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGO. OFFICE: ALEMBIC ROAD, VADODARA- 390 003. •T EL: (0265) 2280550, 2280880 Website : www.alembicpharmaceuticals.com •E-mail: alembic@alembic.co.in • CIN: L24230GJ2010PLC061123
Page 2
ALEMBIC PHARMACEUn CAlS U MITT D CIN:l24230Gl2010PLC061123 Regd.Office: Alembic Road, Vadodara · 390 003 Tel : 0265 6637000 Email : apl.investors@alembic.co.in Website : www.alembicpharmaceutieals.com Statement of Consolidated Unaudited Financial Results for the quarte r and half year ended :,om septemt>er, 2020 Rs . C .m rores Quarte r Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited ) (Unaudlted) (Audited) 1 Revenue from Operations 2,603.48 2,149.77 1,910.15 4,753.25 3,620.87 7,344.90 2 Other Income 15.11 14.93 6.91 30.04 13.41 54.41 3 Total Income 2,618.59 2,164.70 1,917.06 4,783 .29 3,634.28 7,399.31 4 Expenses (a) Cost of Materials cnnsumed 599.64 517.30 463.14 1,116.94 894.41 1,747.38 (b) Purchase or stock-In-trade 177.22 120.50 126.82 297.73 235.98 508.88 (c) Changes in Inventories or finished goods, Stock in trade and WIP (91.09) (17.72) (74.04) (108.81) (207.06) (271.81) (d) Employee benefits expense 503.75 473.94 437.54 977.70 860.31 1,731.93 (e) Finance Costs 38.26 27.61 24.23 65.86 47.75 93.63 (f) Depredation &. Amortization Expense 100.80 97.71 76.07 198.52 149.84 318.55 (g) Other Expenses 850.69 723.89 641.00 1,574.58 1,240.19 2,510.06 Total Expenses 2,179.27 1,943.23 1,694.76 4,122.51 3,221.43 6,638.61 5 Profit before Share of Profit / (Loss) of Assaci ates and Joint 439.31 221.47 222.30 660.79 412.85 760.69 Ventures 6 Share or Profit/ (Loss) of Associates Iii Joint Ventures (1.37) 0.39 1.42 (0.98) 0.97 0.24 7 Profit Before Exceptional Item and Tax 437.95 221.86 223.72 659.81 413.82 760.94 8 Exceptional Item • Refer Note No. 3 - . . . . (66.99) g Profit Before Tax 437.95 221.86 223.n 659.81 413.82 693.95 10 Tax Expense (i) Current Tax 98.67 44.35 46.59 143.02 68.81 127.60 (Ii) Deferred Tax 5.38 5.15 (6.59) 10.52 7.67 (104.48) 11 Profit for the Period before non-co ntrolling interests 333.91 172.36 183.71 506.27 337.34 670.83 12 Non-controlling Interests 1,26 0.71 1.00 1.97 1.75 3.94 ' 13 Profit for the Period after non-controlling interes ts 335.17 173.07 184.71 508.23 339.09 674.77 14 Other Comprehensive Income A (I) Items that will not be reclassified to profit/ (loss) (2.69) (0.49) (7.18) {3.18) (7.65) (6.96) (ll) Income tax relating to items that will not be redassified to profit I 0.68 0.12 1.25 0.80 1.34 0.93 (loss) B (I) Items that will be reclassified to profit/ (loss) (4.17) 3.14 10.59 (1.04) 11.69 30.89 (II) Income tax relating to items that will be reclassified to prom: / (loss) 1.14 (0.49) . 0.65 . Total Other Comprehensive Income (A+B) (5.05) 2.28 4.67 (2.77) 5.38 24.86 15 Total Comprehensive Income for the period (11+14) 328.86 174.63 188.38 503.50 342.12 695.69 Attributable to: • Non-controlling Interests (1.35) (0.70) (1.10) (2.05) (1.86) (4.41) • Owners of the Company 330.21 175.33 189.49 505.54 344.58 700.09 16 Earnings per share· Basic & Diluted (in Rs.) 17.05 8.80 9.40 25.86 17.25 34.33 17 Paid up Equity Share capital (Face Value of Rs 2/· each) 39.31 39.31 39.31 39.31 39.31 39.31 18 Other Equity 5,635.50
Page 3
Not es : The abo ve consolidated results have been recommended by the Audit Committee and approved by the Board of Directors of the Company. The results have been subjected to review by the statutory auditors of the Company. The report of the statutory auditors Is unqualified. 2 The Company is engaged In Pharmaceuticals business only and therefore, there is only one reportable segment. 3 Exceptional Items for the year ended 31st March 2026 comprised Rs. 48.64 crore relating to employee benefit obligations arising from the revised definition of wages under the Labour Codes, and a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility dassified as held for sale under Ind AS 105. 4 For year ended 31st March 2026, consequent to the Finance Act amendment, the Company reassessed deferred tax assets and tax credits, and the resulting Impact has been recognised as a credit in the Statement of Profit and Loss. 5 DISCiosures as per Regulation 52(4) of the SEBI (Listing Obligations and Dlsdosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder: Sr. Quarter Ended Half Year Ended Year Ended No Pilrtiai lal'5 30.09.2025 30.09.2026 30.09.2025 31.03.2026 30.09.2026 30.06.2026 a Debt-Equity Ratio (in times) 0.25 0.28 0.27 0.25 0.27 0.24 Debt/ Net Worth [Debt : Total Debt ( Short tenn + Long term) Net worth : Share Capital + Other Equity) b Debt Service Coverage Ratio (in times ) 10.99 7.63 10.23 9.55 9.67 6.91 (Profit before tax+interest) / ( Interest + schedule principal repayments of l ong term debt) Annualised C Interest Service Coverage Ratio (in times) 12.45 9.04 10.23 U .02 9.67 8.41 (Profit before tax+interest)/ lnterest d Net Worth (Rs. in Crores) 5,950.55 5,856.21 5,322.35 5,950.55 5,322.35 5,680.88 ( Equity capital + Other Equity exduding fair value change on financial Instruments through OCI) e Cum ,nt Ratio (in times) 1.69 1.69 1.59 1.69 1.59 1.75 Current Asset/ Current Liabilities f Long Term Debt to working capital (in times) o.os 0.06 0.02 0.05 0.02 0.07 Long Tenn Borrowings (Ind. Current Maturities)/ (Current Assets • Current Liabilities) g Bad Debts to Accounts Receivable Ratio {o/o) - . . - 0.04% 0.07% Bad Debts/ Accounts Receivable h Curr ent Uability Ratio (in times) 0.86 0.85 0.89 0.86 0.89 0.84 Current Liabilities / Total Liabilities I Total Debts to Total Assets (In times) 0.16 0.18 0.18 0.16 0.18 0.16 (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets J Debtors Turnover Rati o (in times) 6.11 5.20 5.48 s.ss 5.24 5.05 (Value of Sales and Service/ Average Debtor) Annualised k Inventory Turnover (in times) s.90 5.03 4.90 5.40 4.68 4.67 (Sale of products/ Average WIP, FG and Stock in trade Inventory) Annualised I Operating Margin (0/o) 22.21•.1, 16.18% 17.02% 19.480/o 16.93% 16.03% EB!TDA (before E><ceptlonal Items)/ ReVenue from OperatiOns m Net Profit Margin( % ) 12.870/o 8.05% 9.67% 10.690/o 9.36% 9.19% (Net Profit after taxes and share of Profit/(L<>ss) of Associates and Joint Ventures)/ Revenue ~ m Operations ' For Alembic Pharm aceuticals Umite d Place : Vadodara Date : 4th November,2026 Chirayu Amin Chairman Visit us at www .atembicpharmaceuticals.com
Page 4
Alembic Pharmaceuticals Limited Statement of Assets and Liabilities - Conso lidated Particulars Rs • in C rores As at 30th As at 31st September, 2026 March, 2026 CUnauditedl /Audited\ 2,914,11 2,843.59 542.84 633.70 327.83 237.08 51,47 49.70 116,18 113.17 36.42 27.71 260.62 269.61 28.58 15.43 2,653,73 2,510.64 1,896.15 1,466.30 254.23 196.37 7.54 6.33 14.24 13.89 20.88 10.68 375,86 338.38 30,00 30.00 9,530.68 8,762.59 A ASSETS 1 Non-cu rrent assets (a) Property, plant and equipment (bl capital work-in-progress (c) Other Intangible assets {d) Intangible assets under development (e) Financial Assets (i) Investments (ii) Investment accounted for using Equity Method (fl Deferred tax assets (net) (g) Other non-current assets 2 Current assets {a) Inventories (bl Financial Assets - Trade receivables - Cash and cash equivalents - Bank balances other than cash and cash equivalents - Other financial assets (c) Current Tax Assets (Net) (d) Other current assets Assets classified as held for sale TOTAL -ASSETS B EQUITY AND UA8IUTI ES 1 Equity (a) Equity Share capital (bl Other Equity (c) Non-controlling Interests Equity attributable to owners of the Company Total Equity 1--- - = ;..:o..= ~ +- - - =- ;...;c;~ c....i 39.31 39.31 5,905.16 5,635.50 5,944.47 5,674.81 (7.87) (5.83) 5,936.60 5,668.98 90.52 121.92 31.56 44.76 165.86 152.91 207.58 180.18 2 Non-current liabilities (a) Financial liabilities - Borrowings - Lease liabilities (b) Provisions { c) Other Non current Liability 3 Current liabilities {a) Financial liabilities - Borrowings - Lease liabilities - Trade payables A) Due to Micro and Small Enterprises B) Due to other than Micro and Small Enterprises - Other financial liabilities (b) Other current liabilities ( c) Provisions (d) Current Tax Liabilities (Net) TOTAL - EQUITY AND U ABIUTIES 1,399.49 1,238.93 25.39 24.33 64.00 59.77 1,095.08 775.31 170.18 278.54 101,73 70.76 119,06 111.21 123.63 34.98 9,530,68 8,762.59 · Place : Vadodara Date : 4th November,2026 For Alembic Pharmaceuticals Limited ~ -u-A-m- in _ Chairman Visit us at www .alembicpharmaceuti cals.com
Page 5
Rs. in Crores For the Half Year for the Half year ended 30th ended 30th September, 2026 September, 2025 (Unaudited) (Unaudited) 659.81 413.82 0.98 (0.97) 198.52 149.84 65.86 47.75 (5.10) (0.23) (0.77 ) (0.19) 12.00 28.35 (3.02) (1.!H) 0.05 o.oo 0.09 1.89 928. 37 639.28 (143.08) (252.56) (487.49) 107.12 (31.05) (34.68) 326.39 3.47 24.43 (20.22) 17.61 (5.17) 635.18 437.25 (63 .80) (34.33) 571.38 402.92 Alembic Pharmaceuticals Limited Consolidated Statement of Cash Flows For the half year ended 30th September, 2026 Parti culars A CASH FLOWS FROM OPERATI NG ACTIVITI ES: Net Profit Before Tax as per Statement of Profit and Loss (After Exceptional item) Adjustments for: Share of (Profit) / Loss of Associates and Joint Ventures Depreciation and amortisation Interest Expense Interest Income Dividend Income / Gain on Sale of Investments Unrealised foreign exchange (gain) / loss (net) Fair value (gain)/ loss on financial Instruments at fair value through profit or loss Provision / write off for doubtful trade receivables Sundry balances written off / written-back (net) Loss/(Profit) on sale of Asset Operating Profit before change in warlcing capital Worklng capital changes: (Increase) In Inventories (Increase) In Trade Receivables (Increase) In Other Assets Increase In Trade Payables Increase/(Decrease) In Other Uablllties Increase/(Decrease) In Provisions Cash generated from operations Direct taxes paid (Net) Net Cash inflow from Operating Activities (A) 8 CASH FLOWS FROM INVESTING ACTIVITI ES: Proceeds from Sale of Asset Interest received Dividend / Gain on Sale of Investments Purchase of Property , Plant & Equipments and capital Advance Purchase of Intangible assets (lnduding Intangible assets under Development) Investment In Joint Venture Net Cash inflow from Investing Activities (B) C CASH FLOWS FROM FINANCING ACTIVITI ES: 0.05 5.07 0.77 (169.04) (155.58 ) (9-60 ) 0.41 0.19 (234.17) (53.48) (328.341 (287.05) Proceeds from long term borrowings Net Proceeds/ {Payments) in short term borrowings Payment of lease liabilities Change in Restricted Bank Balances other than cash & cash Equivalents Dividends paid Interest and other finance costs Net Cash inflow from Financing Activities (C) Net (Decrease)/ Increase in cash and cash equivalents (A+B+C) II . Cash and cash equivalents at the beginning of the Year :n. Cash and cash equivalents at the end of the period (I+II ) IV. Cash and cash equivalents at the end of the period Balances with Banks cash on hand Cash and cash equivalents U 7.6S {14.98) (0.85) (23 5.88 ) (61,13) 39.95 178.45 (12.29) (2.22) (216.22) (52.64) 57-86 50.90 (185..19) (64.97) 196.37 254.23 83.48 134.38 254-03 0.20 134.14 0.23 254.23 134.36 For ~lemblc Pharmaceuticals Limited # - Chlrayu Amin Chairman Place : Vadodara Date : 4th November,2026 Visit us at www.alemblcpharmaceutlcals.c.om
Page 6
kkc & associates Up Chartered Accountants (formerly Khimji Kunverji & Co LLP) Independent Auditor's Review Report on unaudited consolidated financial results for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 of Alembic Pharmaceuticals Limited under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Alembic Pharmaceuticals Limited Introduction 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Alembic Pharmaceuticals Limited ('the Parent' or 'the Company') and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group') and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associate for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the statement for identification purposes only. 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard {'Ind AS') 34 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. Scope of Review 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ('the ICAI'). A review of interim financial information consists of making inquiries, primarily of persons responsible forf inancial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular Issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable. 4. The Statement includes the interim financial results of entities mentioned in Annexure A. Sunshine Tower, Level 19, Senapati Ba pat Marg, Elphinstone Road, Mumbai 400013, India T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Page 1 of 5 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India
Page 7
kkc & associates llp Chartered Accountants (formerly Khimji Kunverji & Co LLP) Conclusion 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS specified under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. Other Matters 6. We did not review the interim financial result of 1 subsidiary included in the Statement, whose interim financial result, reflect total assets (before consolidation adjustment) of Rs.2,454.06 crore as at 30 September 2026, reflect total revenue (before consolidation adjustment) of Rs.1,084.70 crore and Rs.1,819.53 crore, total net (loss) after tax (before consolidation adjustment) of Rs.21.05 crore and Rs.46.99 crore, total comprehensive loss (before consolidation adjustment) of Rs.21.05 crore and of Rs. 46.99 crore, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustment) of Rs. 40.85 crore for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. This interim financial result has been reviewed by other auditor and their report, vide which they have issued an unmodified conclusion have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. 7. The Statement includes the interim financial results of 7 subsidiaries which have not been reviewed by their auditors, whose financial results reflect total assets (before consolidation adjustment) of Rs. 401.40 crore as at 30 September 2026, reflect total revenue (before consolidation adjustment) of Rs. 216.10 crore and Rs. 460.43 crore, total net loss (before consolidation adjustment) after tax of Rs. 13.84 crore and Rs. 5.62 crore, total comprehensive loss (before consolidation adjustment) of Rs. 13.84 crore and Rs. 5.62 crore for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustment) of Rs. 33.02 Crore for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. The Statement also includes the Group's share of net profit after tax (before consolidation adjustment) of Rs. 0.16 crore and Rs. 0.35 crore and total comprehensive income (before consolidation adjustment) of Rs. 0.16 crore and Rs. 0.35 crore for the quarter ended 30 September 2026 and for the period from 01 September 2026 to 30 September 2026 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information/ financial results which have not been these interim financial information/ financial results are not material to the Group. Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Page 2 of 5 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India
Page 8
kkc & associates Up Chartered Accountants (formerly Khimji Kunverji & Co LLP) 8. The Parent Company's management has converted the interim financial results of 8 subsidiaries, which are located outside India, from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries is based on the review report of such other auditor and Management certified interim financial results as referred in above paras and the conversion adjustments prepared by the management of the Parent Company and reviewed by us. Our conclusion on the statement is not modified in respect of above matters. For KKC & Associates LLP Chartered Accountants {formerly Khimji Kunverji & Co LLP) Firm Registration Number: 105146W/W100621 Tejas Parikh Partner ICAI Membership No: 123215 uo1N: ex, ,2 ~~ ,~ :ro :I: CJ'V\-r Jf3~ Place: Mumbai Date: 04 November 2026 Page 3 of 5 Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +9122 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India
Page 9
kkc & associates Up Chartered Accountants (formerly Khimji Kunverji & Co LLP) AnnexureA List of Entities :- Sr.No Name of Entity Relation 1 Alembic Pharmaceuticals Limited Parent 2 Alembic Pharmaceutical Inc. Subsidiary a Onkar Realty LLC 1 Step down Subsidiary b Alembic Labs LLC 2 Step down Subsidiary C Utility Therapeutics Limited 3 Step down Subsidiary d Alembic Therapeutics LLC 4 Step down Subsidiary 3 Alembic Global Holding SA (AGH) Subsidiary a Alembic Pharmaceuticals Australia Pty Ltd Step down Subsidiary b Alembic Pharmaceuticals Canada Ltd Step down Subsidiary C Alembic Pharmaceuticals Europe Limited Step down Subsidiary d Genius LLC 5 Step down Subsidiary e Alnova Pharmaceuticals SA 6 Step down Subsidiary f TicTwo Therapeutics Inc. Step down Subsidiary g Alembic Lifesciences Inc. Step down Subsidiary h Rhizen Pharmaceuticals AG Associate of AGH i Dahlia Therapeutics SA 6 Associate as a subsidiary of Rhizen Pharmaceuticals AG j Alembic Marni SpA 7 Joint venture k SPH Sine Alembic {Shanghai) Pharmaceutical Joint Venture Technology Limited 8 I 17989311 Canada lnc.9 Joint Venture - 4 Alembic Pharmaceuticals Chile SpA Subsidiary ~ssoo~ q,, ~.-! <.:n-~· d a> 5 Alembic Pharmaceuticals S.A.de C.V. Subsidiary (J d•1:; ,8 (II ) ~ t8:) ·,:ants ::: ~ jc·-? Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +91 22 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India Page 4 of 5
Page 10
kkc & associates Up Chartered Accountants (formerly Khimji Kunverji & Co LLP) 6 Alembic Pharmaceuticals Scientific Office L.L.C10 Subsidiary 7 Alembic Pharmaceuticals (Thailand) Ltd11 Subsidiary 8 Alembic Lifesciences Philippines lnc iz Subsidiary 9 Alembic Pharmaceuticals GmbH13 Subsidiary 10 Fenix Research Labs Private Limited 14 Associate 1 The entity was dissolved on 19 September 2024 2 The entity was dissolved on 26 September 2024 3 The entity has been acquired on 2 July 2025 4 The entity has been incorporated on 19 March 2025 5 Genius LLC is based out in Ukraine. The investment value in Genius LLC is already provided for by AGH during the F.Y.2022-2023. As at 30 September 2026, Genius LLC does not have any asset/liability, and no transaction is entered during the quarter ended 30 September 2026. As per Intimation 6 December 2024 to BSE Limited and National Stock Exchange of lndia limited by Parent company, this company has been non-operation and is in the process of dissolution. 6 As per Intimation 6 December 2024 to BSE Limited and National Stock Exchange of lndia limited by Parent company, these company have been non-operation and is in the process of dissolution. 7 The financial results of this entity have not been received or prepared by the Alembic Global Holding SA and no further share of loss is required to be borne by the Group as the entire Equity capital and loan given to it is fully provided for in earlier year. As per intimation dated 6 December 2024 to BSE Limited and National Stock Exchange of India Limited by Parent Company, this Company has been non-operational and is in the process of dissolution. 8The joint venture agreement was entered into on 7 May 2019. We are informed that the Group has invested Rs. 0.46 Crores and the operations have not started till 30 September 2026, and therefore, there are no transactions for the quarter ended 30 September 2026 and accordingly, no share of profit or loss has been consolidated in these interim financial results. This Joint Venture is in the process of product registration and will take due course of time for registration and commencement of operations. 9 The entity was incorporated as joint venture on 3 June 2026 1° Conversion from Branch to Subsidiary on 27 October 2025 11 The entity has been incorporated on 6 March 2026 12 The entity has been incorporated on 26 August 2026 13 The entity has been incorporated on 21 April 2026 14Formerly known as lncozen Therapeutics Private Limited. Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +9122 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Page 5 of 5 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India
Page 11
ALEMBIC PHARMACEUTI CA LS U MITE O O N:U 423 0GJ20 10PLC06l l 23 Regd.Office: Alembic Road, Vadodara • 390 003 Tel : 0265 6637000 Emall : apl.investo.-s@alembic.co.in Website : www.alombicpharmacautlcals:.com Statement of Standalone Unaudited Financial Results for the quarte r and half year ended 30th September, 2026 Rs. in Crores Quarter Ended Half Year Ended Year Ended Particulars 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Revenue from Operations 2,391.65 1,868.06 1,796.24 4,259.72 3,290.41 6,651.38 2 Other Income 24.42 14.04 11.49 38.46 19.29 55.90 3 Total Income 2,416.07 1,882.10 1,807.73 4,298. 17 3,309.69 6,707.28 4 Expenses (a) Cost of Materials consumed 599 .64 517.30 463.14 1,116.94 894.41 1,747.38 (b) Purchase of stock-in-trade 134 .24 119.92 97.97 254.16 195.47 394.57 (c) Changes in Inventories of finished goods, Stock in trade and (30.26) (82.24) 22.80 (112.50) (88.70) (121.15) WIP (d) Employee benefits expense 454 .20 416.46 408.12 870.66 804.52 1,612.90 (e) Anance Costs 26.67 21.41 22.81 48.08 45.45 86.51 (f) Depreciation &. Amortization Expense 84.41 82.54 75.64 166.96 149.01 311.00 (g) Other expenses 612.36 550.80 500.90 1,163.16 967.66 1,954.96 Total Expenses 1,88 1.26 1,626.19 1,591.38 3,507.46 2,967.82 5,986.17 5 Profit Before Exceptional It em and Tax 534.81 255.90 216.35 790.72 341.87 721.10 6 Exceptional Item - Refer Note No. 2 - - - - - (66.99) 7 Prof"it Before Tax 534 .81 255.90 216.35 790.72 341.87 654.11 8 Tax Expense {i) Cur.rent Tax 96.00 43.34 36.99 139.34 58.99 115.14 (11) Deferred Tax 29.45 15.61 45.06 - (101.45) 9 Profit for the Period 409.36 196.96 179.36 606.3 2 282.88 640.42 10 Other Comprehensive Income A (i) Items that wiU not be reclassified to profit/ {loss) (2.69) (0.49) (7.18) (3.18) (7.65) (4.61) {ii) Income tax relating to Items that will not be redassified to 0.68 0.12 1.25 0.80 1.34 0.93 profit / (loss) B (i) Items that will be reclassified to profit/ (loss) (4.54 ) l.96 . (2.58) - - {ii) Income tax relating to Items that will be reclassified to profit/ 1.14 (0.49) - 0.65 - - {loss) Total Other Comprehensive Income (.A+B) (5.41) l.09 (5.92) (4.31) (6.31) (3.68) l1 Total Comprehensive Income for the period 403.95 198.06 173.44 602.01 276.57 636.74 12 Earnings per share - Basic & Diluted (In Rs.) 20.83 10.02 9.12 30.85 14.39 32.58 13 Paid up Equity Share capital (Face Value of Rs 2/· each) 39.31 39.31 39.31 39.31 39.31 39.31 14 Other Equity 5,575.95 I
Page 12
1 The above standalone results have been recommended by the Audit Committee and approved by the Board of 01rect0rs of the Company. The results have been subjected to review by the statutory auditors of the Company. The report of the statutory auditors is unqualified, Notes: 2 Exceptional Items for the year ended 31st March 2026 comprised Rs. 48.64 crore re1aung to employee be<>cfit obl lg•tion • arii:l"9 tTOm tha revised definition of wages under the Labour Codes, and a write-down of Rs. 18.35 crore on assets of the Sikkim manufacturing facility ciassified as held for sale under Ind AS 105. 3 For the year ended 31st March 2026, consequent to the Finance Act amendment. the Company reassessed deferred tax assets and tax credits, and the resulting impact has been recognised as a credit In the Statement of Profit and \.OSs. 4 Disclosures as per Regulation 52(4) of the SEBI (Listing Obligations and Dlsciosure Requirements) RegulatiOns, 2015 as appllcable and additiOnal Informations are given hereunder; Sr. Particulars Quarter Ended Half Year Ended Year Ended No 30,09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 a Debt•Equity Ratio (in times) 0.19 0.22 0.25 0.19 o.25 0.20 Debt/ Net Worth {Debt : Total Debt ( Short term + Long term) Net worth : Share Capital + Other Equity] b Debt Service Coveraae Ratio (in timesl 21.06 12.95 10.49 17.45 8.52 8.56 (Profit before tax+interest) / (Interest + schedule principal repayments of Long term debt) Annuallsed C Interest Service Coveraae Ratio (in timesl 21.06 12.95 10.49 17,45 8.52 8.56 (Profit before tax+lnterest)/ Interest d Net Worth (Rs. in erores) 5,987.47 5,819.40 5,258.15 5,987.47 5,258.15 5,621.34 (Equity capltal + Other Equity exduding fair value change on financial Instruments through 00 ) e Current Ratio (In times) 1.85 1.75 1.59 1.85 1.59 1.70 Current Asset / Current Uabilltles f Bad Debts to Accounts Receivable Ratio ('Vo) . . . . 0.03% 0.03% Bad Debts/ Accounts Receivable g Current Uabillty Ratio (In times) 0.93 0.94 0.95 Q.93 0.95 0.93 Current Liabilities/ Total Uabilitles h Total Debts to Total Assets (in ti mes) Q.13 0.15 0.18 Q.13 0.18 0.15 (Long term Borrowings+ Short Term Borrowings+ Lease liability)/ Total Assets 4.39 4.24 i Debtors Turnover Ratio (in times) 5.18 4.27 4.75 4.63 (Value of Sales and Service / Average Debtor) Annualised J Inventory Turnover (in times) 7.35 5.85 6.08 6.57 5.62 5.63 (Sale of products/ A"erage WIP, FG and Stock in trade Inventory) Annualised k Opera ting Margin (Ofo) 27.010/o 19.26% 17.53% 23.61% 16.30% 16.82% EBITDA (before Exceptional items)/ Revenue from Operations I Net Profit Margin( % ) 17.12 0/o 10.54% 9.99% 14.23% 8.60% 9.63% Net Profit after taxes / Revenue from OperatJons For Alembic Pharmaceuticats.Umited Chirayu Amin Chairman Place : Vadodara Date : 4th No,,ember,2026 Visit us at www.alembicpharmaceuticals.com
Page 13
Alem bic Pharmaceuticals li mited Stateme nt of Assets and Liabilities - Standalone Rs in Crores As at 30th As at 31st Particulars September, 2026 March, 2026 ,unaudited\ (Audited) A ASSETS 1 Non-current assets (a) Property , plant and equipment 2,893.00 2,828.42 (b) Capital work-in-progress . 542.84 633.70 (c) Intangible assets under development 51.47 49.70 (d) Financial Assets (i) Investments 276.79 271.40 (ii) Loan 77.21 141.93 ( e) Deferred tax assets ( net) 135.40 179.66 (f) Other non-current assets 28.58 15.43 2 Current assets (a) Inventories 2,194.92 2,048.16 (b) Financial Assets - Trade receivables 2,032.98 1,603.75 - cash and cash equivalents 6.64 22.67 - Bank balances other than cash and cash equivalents 7.27 6.07 - Loans 65.54 12.19 - Others financial assets 13.68 13.40 (c) Current Tax Assets (Net) 0.03 10.68 (d) Other current assets 328.04 284.10 Assets classified as held for sale 30.00 30.00 TOTAL - ASSETS 8,684.39 8,151.25 B EQUITY AND U ABIUTI ES 1 Equity (a) Equity Share capital 39.31 39.31 (b) Other Equity 5,942.08 5,575.95 2 Non-current liabilities (a) Financial liabilities - Lease liabilities 17.77 26.92 (b) Provisions 165.86 152.91 3 Current liabilities (a) Financial liabilities - Borrowings 1,111.so 1,149.49 - Lease liabilities 19.83 21.67 - Trade payables A} Due to Micro and Small Enterprises 64.00 59.77 6) Due to other than Micro and Small Enterprises 822.13 600.93 - Other financial liabilities 166.17 289.19 (b) Other current llabillties 98.79 70.27 ( c) Provisions 118.28 110.42 (d) Current Tax Liabilities (Net) 118.67 54.41 TOTAL - EQUITY AND U ABIUTI ES 8,684.39 8,151.25 Place : Vadodara Date : 4th November,2026 For Alembic Pharmaceuticals Limited 4, .. m- in _ _ __.._ Chairman Visit us at www .alembicpharmaceuticals.com
Page 14
Alembic Pharmaceuticals Limit ed · Standalone Sta tement of Cash Flows For the half year ended 30th September, 2026 Net Profit Before Tax as per Statement of Profit and Loss {After Exceptional item) Adjustments for: Depreciation and amortisation Interest Expense Interest Income Dividend Income/ Gain on Sale of Investments Unrealised foreign e,cchange (gain)/ loss (net) Fair value (gain}/ loss on financial instruments at fair value through profit or loss Provision / write off for doubtful trade receivables Sundry balances written off/ written-back (net) Loss/(Profit) on sale of Asset Operating Profit before change in working capital Rs. In Crores For the Half Year for the Half year ended 30th ended 30th September, 2026 Septemt>er, zoz s (Unaudited) (Unaudited) 790.72 341.87 166.96 149.01 48.08 45.45 (9.76) (3.26) (0.77) (0.19) 12.00 28.35 (3.02) (1.04) 0.05 o.oo Q.09 1.89 1,004.29 562.14 (146.76) (134.22) (489.07) 29.63 (37.45) (31.51) 227.82 (44.85) 20.59 (20.75) 17.62 (5.12) 597.04 355.33 (63.78) (23.07) 533.26 332.26 Particulars A CASH FLOWS FROM OPERATING ACTIVITIES: Working capital changes: (Increase) In Inventories {lncrease)/Decrease tn Trade Receivables (Increase) In Other Assets Increase In Trade Payables Increase/(Decrease) In Other Uabilitles Increase/(Decrease) In Provisions Cash generated from operations Direct taxes paid (Net) Net Cash inflow from Operating Activities (A) B CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from Sale of Asset Repayment of Loan by Subsidiary Interest received Dividend / Gain on Sale of Investments received Purchase of Property, Plant & Equipment and Capital Advance Purchase of intangible assets under Development Payment towards purchase of investments Investment In Subsidiary Net Cash inflow from Investing Activities (B) C CASH FLOWS FROM FINANCING ACTIVffi ES: Net Proceeds/ {Payments) in short term borrowings Payment of lease liabilities Increase in Restricted Bank Balances other than Cash & Cash Equivalents Dividends paid Interest and other finance costs Net cash inflow from Finandng Activities (C) I Net (Decrease)/ Increase in cash and cash equivalents (A+B+C) II . Cash and cash equivalents at the beginning of the Year :II. cash and cash equivalents at the end of the period (1+II ) J.V. Cash and cash equivalents at the end of the period Balances with Banks Cash on hand Cash and cash equivalents a.OS 14.41 (6.59) 6.01 0.04 0.77 0.19 {168.77) (233.32) (48.11) (11.86) (2.37) (0.03) (209.87), (239.71) (37.99) 195.78 (12.92) (11.43) (0.85) (0.00) {235.88) (216.22) {51.78) (51.93) (339.41) (83.81) (16.02) 8.75 22.67 14.23 6.64 22.97 6.44 22.74 0.20 0.23 6.64 22.97 for Alembic Pharmaceuticals Limited Place : Vadodara Date : 4th November,2026 Visit us at www .alembicpharmaceuticals.com Chairman
Page 15
kkc & associates Up Chartered Accountants (formerly Khimji Kunverji & Co LLP) Independent Auditor's Review Report on unaudited standalone financial results for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 of Alembic Pharmaceuticals Limited under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Alembic Pharmaceuticals Limited Introduction 1. We have reviewed the accompanying statement of unaudited standalone financial results of Alembic Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). We have initialled the statement for identification purposes only. 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013{"the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. Scope of Review 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the !CAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +9122 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Page 1 of 2 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India
Page 16
kkc & associates lip Chartered Accountants (formerly Khimji Kunverji & Co LLP) Conclusion 4. Based on our review conducted as above, nothing has come to our att ention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS under Section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For KKC & Associates LLP Chartered Accountants (formerly Khimji Kunverji & Co LLP) Firm Registration Number: 105146W/W100621 Tejas Parikh Partner ICAI Membership No: 123215 UDIN: ~ ~ l :2.~ ol ,s;- E,-L.H F rt:r 45 l.t \ Place: Mumbai Date: 04 November 2026 Sunshine Tower, Level 19, Senapati Bapat Marg, Elphinstone Road, Mumbai 400013, India T: +9122 6143 7333 E: info@kkcllp.in W: www.kkcllp.in LLPIN: AAP-2267 Page 2 of 2 Suite 52, Bombay Mutual Building, Sir Phirozshah Mehta Road, Fort, Mumbai 400001, India